O02 – 68Ga-DOTATATE PET/CT Imaging for Advanced Neuroendocrine Carcinoma in the United States

Published in 2011 Listed under Other

Eric H. Liu, Jeff Clanton, Dominique Delbeke, Martin Sandler, Bill Martin, Ronald C. Walker

O03 – Open-Label Phase 2 Clinical Trial of LX1606 / LX1032 in Europe: A Novel Agent for Reducing Serotonin Production in Carcinoid Syndrome

Published in 2010 Listed under Other

Phil Brown, Kenny Frazier, Jessica Jackson, Shanna Jackson, Joel Frieman, Brian Zambrowicz

O07 – Tumor and Normal Tissue Uptake of 68Ga-DOTA-tyr3- Octreotide after Treatment with Unlabeled Octreotide in Patients with Carcinoid Tumors and Pancreatic Neuroendocrine Tumors

Published in 2010 Listed under Other

Yusuf Menda, MD, Michael Schultz, PhD, David Bushnell, MD, Thomas O’Dorisio, MD, M. Sue O’Dorisio, MD, PhD

O10 - The Use of Octreotide LAR in Routine Canadian Practice: Dosing Considerations and Persistence Rates

Published in 2020 Listed under Other

S. Singh, W. Cheung, H. Gourdeau

ABSTRACT ID: 178

O11 - Neuroendocrine Carcinoma of the Rectum & Anus: Patient Characteristics and Treatment Modalities

Published in 2020 Listed under Other

B. Ueberroth, A. Liu, T. Halfdanarson, M. Sonbol

ABSTRACT ID: 191

O2 - Development and Validation of the Disease-Specific QOL-CD Quality of Life Questionnaire for Patients with Cushing’s Disease

Published in 2020 Listed under Other

M. Cusimano, T. Huang, A. Marchie, H. Smyth, K. Kovacs

ABSTRACT ID: 108

O3 - Survey of Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumor (NET) Patients (SCAN) – USA and Canada vs Global Diagnosis of NETs

Published in 2020 Listed under Other

E. Gellerman, J. Herman, M. McDonnell, D. Van Genechten, M. Pavel, D. O'Toole, H. Singh, J. Chen, J. Howe, S. Singh, C. Bouvier, C. Rodien-Louw, S. Leyden, S. Dureja, T. Kolarova

ABSTRACT ID: 126

O4 - Identifying Care Processes Promoting Person-Centred Care for Patients Diagnosed With Neuroendocrine Tumours (NETs)

Published in 2020 Listed under Other

J. Hallet, V. Zuk, L. Moody, D. Chan, M. Michael, T. Halfdanarson, R. Pommier, S. Myrehaug, R. Goodwin, C. Law, J. Herman, S. Sohail, F. Wright, L. Gotlib Conn

ABSTRACT ID: 129

O5 - Supporting Accurate Patient Information for An Uncommon Malignancy: Evaluation of the Quality of Information on Neuroendocrine Tumors (NETs) on the Internet

Published in 2020 Listed under Other

S. Sohail, V. Zuk, T. Halfdanarson, D. Chan, S. Pattison, R. Vasdev, C. Law

ABSTRACT ID: 131

O7 - Stereotactic Ablative Radiotherapy for the Management of Neuroendocrine Liver Metastases

Published in 2020 Listed under Other

J. Hudson, H. Chung, W. Chu, A. Taggar, L. Davis, J. Hallet, C. Law, S. Singh, S. Myrehaug

ABSTRACT ID: 166

O8 - Role of Chromogranin A-derived Fragments as Biomarkers for Pancreatic Neuroendocrine Tumors (PanNET)

Published in 2020 Listed under Other

V. Andreasi, S. Partelli, M. Manzoni, B. Colombo, F. Muffatti, A. Corti, M. Falconi

ABSTRACT ID: 168

O9 - Patient Experience with Somatostatin Analog Treatments for Neuroendocrine Tumors: Insight from Qualitative Interviews

Published in 2020 Listed under Other

C. Seo, E. Horodniceanu, R. Shah, G. Goldstein, D. Ray, B. Bennett, A. Phan, K. McCarrier

ABSTRACT ID: 171